Courtney DiNardo, MD, MSCE

Articles

Evolving Horizons: MDS Diagnosis and Risk Stratification in 2024

December 20th 2024

The panelists discuss the newest risk stratification tool, IPSS-M.

Dr DiNardo on the FDA Approval of Ivosidenib in Relapsed/Refractory, IDH1+ MDS

October 24th 2023

Courtney D. DiNardo, MD, MSCE, discusses the significance of the FDA approval of ivosidenib in patients with relapsed/refractory, IDH1-mutated myelodysplastic syndromes.

​​Dr DiNardo on Alternative Triplet Regimens For Select Patients With AML

September 14th 2023

Courtney DiNardo, MD, MSCE, discusses triplets that serve as alternatives to standard-of-care approaches with azacitidine and venetoclax doublet therapy in select patients with acute myeloid leukemia.

Women in Oncology: Leaving Passionate Legacies

October 28th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the scientific achievements they have witnessed in the field of leukemia and their hopes for the future of treating this disease.

Women in Oncology: The Value of Female Leadership

October 28th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss how they turned career obstacles into opportunities and what they have learned from being women in the leukemia field.

Women in Oncology: Opportunities for Success Through Mentorship

October 27th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the importance of strong mentorship relationships and the unique growth opportunities they found at different points of their careers.

Women in Oncology: Actively Preparing for Advances in Leukemia Treatment

October 27th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the toughest challenges they faced in the leukemia field at the start of their fellowships and careers.

Dr. DiNardo on the FDA Approval of Oral Azacitidine in AML

September 1st 2020

Courtney DiNardo, MD, MSCE, discusses the FDA approval of oral azacitidine (CC-486) in acute myeloid leukemia (AML).

Dr. DiNardo on the Rationale for the Pooled Analysis Evaluating Venetoclax in AML

June 26th 2020

Courtney DiNardo, MD, MSCE, discusses the rational​e for a pooled analysis evaluating venetoclax in acute myeloid leukemia.

Dr. DiNardo on the Results of the VIALE-A Trial in AML

June 13th 2020

Courtney DiNardo, MD, MSCE, discusses the results of the phase 3 VIALE-A trial in acute myeloid leukemia (AML).

Dr. DiNardo on Timing and Impact of Response to Venetoclax Combinations in AML

June 11th 2020

Courtney DiNardo, MD, MSCE, iscusses findings from a pooled analysis examining venetoclax (Venclexta) combination treatment in acute myeloid leukemia.

Dr. DiNardo on Timing and Impact of Response to Venetoclax Combinations in AML

June 10th 2020

Courtney DiNardo, MD, MSCE, discusses findings from a pooled analysis examining venetoclax (Venclexta) combination treatment in acute myeloid leukemia.

Dr. DiNardo on the Role of Venetoclax in AML

June 3rd 2020

Courtney DiNardo, MD, MSCE, discusses the role of venetoclax (Venclexta) in acute myeloid leukemia (AML).

Dr. DiNardo on Rationale to Combine Enasidenib and Azacitidine in AML

February 7th 2020

Courtney DiNardo, MD, MSCE, discusses the rationale to combine enasidenib (Idhifa) with azacitidine in acute myeloid leukemia.